A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)
Status:
Completed
Trial end date:
2021-03-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to combine the PDR001 checkpoint inhibitor with each of four
agents with immunomodulatory activity to identify the doses and schedule for combination
therapy and to preliminarily assess the safety, tolerability, pharmacological and clinical
activity of these combinations.